Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Two New Vaccines Join COVID Fight As China Ships Millions Overseas

Newcomers to Speed Up Slow Domestic Rollout?

Executive Summary

CanSino's adenovirus-based COVID-19 vaccine, along with another one from state-owned Sinopharm grab promot approvals in China as  Beijing shipping millions of doses around the world.

You may also be interested in...



‘Reckless’ State Campaigns Seek To Undermine Western COVID-19 Vaccines

China, Iran and especially Russia have launched campaigns aimed at undermining confidence in Western vaccines, especially Pfizer’s, according to two reports.

‘Reckless’ State Campaigns Seek To Undermine Western COVID-19 Vaccines

China, Iran and especially Russia have launched campaigns aimed at undermining confidence in Western vaccines, especially Pfizer’s, according to two reports.

China Grants Conditional Approval To CNBG COVID Vaccine

State-owned China National Biotec Group becomes the first to get the greenlight for its inactivated virus-based vaccine to prevent COVID-19.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143883

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel